{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T19:03:06Z","timestamp":1790794986409,"version":"4.1.0"},"reference-count":33,"publisher":"MDPI AG","issue":"5","license":[{"start":{"date-parts":[[2025,2,25]],"date-time":"2025-02-25T00:00:00Z","timestamp":1740441600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancers"],"abstract":"<jats:p>Background: The gradual introduction of numerous therapeutic advancements over recent years in the treatment of patients with multiple myeloma (MM) appears to have contributed to significant improvements in overall survival (OS). Methods: We conducted a single-center retrospective observational study, including all MM patients treated at the University Hospital of Jerez de la Frontera, diagnosed between 1 January 2000, and 31 December 2022. Patients were divided into three calendar periods (2000\u20132007, 2008\u20132015, and 2016\u20132022) and two patient groups (candidates and non-candidates for autologous hematopoietic progenitor transplantation). Results: A total of 420 myeloma patients were included in this study, with a median age of 64 years. The median survival steadily improved from 50.7 months (33.8\u201373.2; 95% CI) in 2000\u20132007 to 72.4 months (57.5\u201398.2; 95% CI) in 2008\u20132015 and has not yet been determined in the 2016\u20132022 cohort (p = 0.008). OS improved in all age groups, even in older patients. The median OS in patients not undergoing autologous stem cell transplantation (ASCT) was 38.8 months (31.5\u201351.6; 95% CI) compared with 132.66 months (110.5\u2013150.9; 95% CI) in those who underwent this procedure (p &lt; 0.0001). The introduction of novel drug classes in first-line treatment significantly improved OS compared with traditional chemotherapy (56.7 months). The median OS increased to 78.8 months (95% CI: 68.8\u2013113.3; p = 0.03) with proteasome inhibitors (PIs), 99.4 months (95% CI: 99.4\u2013NA; &lt; 0.0001) with immunomodulatory drugs (IMIDs), and was not determined for anti-CD38 monoclonal antibodies (p = 0.02). Conclusions: Survival outcomes for MM have significantly improved over the past two decades, particularly among younger and ASCT-eligible patients. However, according to all studies, disparities persist across healthcare settings, underscoring the need for equitable access to modern therapies and optimized management strategies.<\/jats:p>","DOI":"10.3390\/cancers17050793","type":"journal-article","created":{"date-parts":[[2025,2,25]],"date-time":"2025-02-25T12:01:17Z","timestamp":1740484877000},"page":"793","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["Evolution of Survival in Patients with Multiple Myeloma over Two Decades: A Real-World Experience from a Medium-Level Hospital"],"prefix":"10.3390","volume":"17","author":[{"given":"Esther","family":"Ortega-Vida","sequence":"first","affiliation":[{"name":"Department of Hematology, University Hospital of Jerez, 11407 Jerez de la Frontera, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abel","family":"Rosado-Rodriguez","sequence":"additional","affiliation":[{"name":"Department of Hematology, University Hospital of Jerez, 11407 Jerez de la Frontera, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rocio","family":"Fe","sequence":"additional","affiliation":[{"name":"Department of Hematology, University Hospital of Jerez, 11407 Jerez de la Frontera, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Victoria","family":"Verdugo","sequence":"additional","affiliation":[{"name":"Department of Hematology, University Hospital of Jerez, 11407 Jerez de la Frontera, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rocio","family":"Gavira","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, University Hospital of Jerez, 11407 Jerez de la Frontera, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sebasti\u00e1n","family":"Garz\u00f3n","sequence":"additional","affiliation":[{"name":"Department of Hematology, University Hospital of Jerez, 11407 Jerez de la Frontera, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2025,2,25]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1002\/ijc.22718","article-title":"Multiple myeloma: A review of the epidemiologic literature","volume":"120","author":"Alexander","year":"2007","journal-title":"Int. J. Cancer."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"7","DOI":"10.3322\/caac.21332","article-title":"Cancer statistics, 2016","volume":"66","author":"Siegel","year":"2016","journal-title":"CA A Cancer J. Clin."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"209","DOI":"10.3322\/caac.21660","article-title":"Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries","volume":"71","author":"Sung","year":"2021","journal-title":"CA A Cancer J. Clin."},{"key":"ref_4","unstructured":"American Cancer Society\u2019s (2024, September 01). Key Statistics About Multiple Mieloma. Available online: https:\/\/www.cancer.org\/content\/dam\/CRC\/PDF\/Public\/8738.00.pdf."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1111\/ejh.13083","article-title":"Rapidly changing myeloma epidemiology in the general population: Increased incidence, older patients, and longer survival","volume":"101","author":"Turesson","year":"2018","journal-title":"Eur. J. Haematol."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"1221","DOI":"10.1001\/jamaoncol.2018.2128","article-title":"Global Burden of Multiple Myeloma: A Systematic Analysis for the Global Burden of Disease Study 2016","volume":"4","author":"Cowan","year":"2018","journal-title":"JAMA Oncol."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1182\/bloodadvances.2016002493","article-title":"Recent trends in multiple myeloma incidence and survival by age, race, and ethnicity in the United States","volume":"1","author":"Costa","year":"2017","journal-title":"Blood Adv."},{"key":"ref_8","doi-asserted-by":"crossref","unstructured":"Hou, Q., Li, X., Ma, H., Fu, D., and Liao, A. (2025). A systematic epidemiological trends analysis study in global burden of multiple myeloma and 29 years forecast. Sci. Rep., 15.","DOI":"10.1038\/s41598-024-83630-x"},{"key":"ref_9","doi-asserted-by":"crossref","unstructured":"Zhou, L., Yu, Q., Wei, G., Wang, L., Huang, Y., Hu, K., Hu, Y., and Huang, H. (2021). Measuring the global, regional, and national burden of multiple myeloma from 1990 to 2019. BMC Cancer, 21.","DOI":"10.1186\/s12885-021-08280-y"},{"key":"ref_10","doi-asserted-by":"crossref","unstructured":"Gadhiya, D. (2023). Global Burden and Trends of Multiple Myeloma in High-Income North America Countries between 1990\u20132019, with Projections of Deaths to 2040: A Benchmarking Analysis for the Global Burden of Disease Study 2019, St. Luke\u2019s University Health Network-Anderson Campus.","DOI":"10.1182\/blood-2023-191338"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"e19509","DOI":"10.1200\/JCO.2024.42.16_suppl.e19509","article-title":"Survival shifts in multiple myeloma: Evaluating the impact of therapeutic advances and racial disparities after a decade of change","volume":"42","author":"Hebishy","year":"2024","journal-title":"JCO"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"2101","DOI":"10.1002\/cam4.1347","article-title":"Epidemiology of multiple myeloma in 17 Latin American countries: An update","volume":"7","author":"Curado","year":"2018","journal-title":"Cancer Med."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"e1406","DOI":"10.1634\/theoncologist.2020-0141","article-title":"Multiple Myeloma Incidence and Mortality Around the Globe; Interrelations Between Health Access and Quality, Economic Resources, and Patient Empowerment","volume":"25","author":"Ludwig","year":"2020","journal-title":"Oncologist"},{"key":"ref_14","doi-asserted-by":"crossref","unstructured":"Broccia, G., Carter, J., Ozsin-Ozler, C., Meloni, F., Pilia, I., De Matteis, S., and Cocco, P. (2022). Time trend and Bayesian mapping of multiple myeloma incidence in Sardinia, Italy. Sci. Rep., 12, Erratum in Sci. Rep. 2022, 12, 3779.","DOI":"10.1038\/s41598-022-06745-z"},{"key":"ref_15","unstructured":"Cancer Statistics Review (2024, September 01). SEER (Surveillance, Epidemiology and End Results) Recent Trends, Available online: https:\/\/seer.cancer.gov\/index.html."},{"key":"ref_16","unstructured":"International Agency for Research on Cancer (2024, September 01). Latest Global Cancer Data. Available online: https:\/\/www.iarc.who.int\/."},{"key":"ref_17","unstructured":"International Association of Cancer Registries (2024, September 01). Cancer Registration Principles. Available online: http:\/\/www.iacr.com.fr\/."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"1915","DOI":"10.1038\/leu.2016.380","article-title":"Trends in overall survival and costs of multiple myeloma, 2000\u20132014","volume":"31","author":"Fonseca","year":"2017","journal-title":"Leukemia"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"e412","DOI":"10.3324\/haematol.2017.183475","article-title":"Dramatically improved survival in multiple myeloma patients in the recent decade: Results from a Swedish population-based study","volume":"103","author":"Thorsteinsdottir","year":"2018","journal-title":"Haematologica"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"S225","DOI":"10.1016\/j.bbmt.2019.12.464","article-title":"Continued Improvement in Survival of Multiple Myeloma Patients: An Institutional Study from 1992\u20132016","volume":"26","author":"Nunnelee","year":"2020","journal-title":"Biol. Blood Marrow Transplant."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"506","DOI":"10.3324\/haematol.2017.178103","article-title":"Outcome and survival of myeloma patients diagnosed 2008-2015. Real-world data on 4904 patients from the Swedish Myeloma Registry","volume":"103","author":"Blimark","year":"2018","journal-title":"Haematologica"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1002\/hon.2205","article-title":"Improved survival of older patients with multiple myeloma in the era of novel agents","volume":"34","author":"Mey","year":"2016","journal-title":"Hematol. Oncol."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1038\/s41375-021-01453-5","article-title":"Mortality trends in multiple myeloma after the introduction of novel therapies in the United States","volume":"36","author":"Binder","year":"2022","journal-title":"Leukemia"},{"key":"ref_24","doi-asserted-by":"crossref","unstructured":"Eisfeld, C., Kaj\u00fcter, H., M\u00f6ller, L., Wellmann, I., Shumilov, E., and Stang, A. (2023). Time trends in survival and causes of death in multiple myeloma: A population-based study from Germany. BMC Cancer, 23.","DOI":"10.1186\/s12885-023-10787-5"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1007\/s00277-019-03858-w","article-title":"Treatment evolution and improved survival in multiple myeloma in Taiwan","volume":"99","author":"Tang","year":"2020","journal-title":"Ann. Hematol."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"8039","DOI":"10.1200\/JCO.2019.37.15_suppl.8039","article-title":"Continued improvement in survival in multiple myeloma (MM) including high-risk patients","volume":"37","author":"Nandakumar","year":"2019","journal-title":"J. Clin. Oncol."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"3600","DOI":"10.1038\/s41375-021-01250-0","article-title":"Intergroupe Francophone du My\u00e9lome (IFM). Improved survival in multiple myeloma during the 2005\u20132009 and 2010\u20132014 periods","volume":"35","author":"Corre","year":"2021","journal-title":"Leukemia"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"1779","DOI":"10.1007\/s00277-021-04481-4","article-title":"Characteristics and survival trends in Finnish multiple myeloma patients-a nationwide real-world evidence study","volume":"100","author":"Toppila","year":"2021","journal-title":"Ann. Hematol."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1182\/bloodadvances.2019000524","article-title":"Long-term outcomes after autologous stem cell transplantation for multiple myeloma","volume":"4","author":"Nishimura","year":"2020","journal-title":"Blood Adv."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"1429","DOI":"10.1007\/s12094-020-02541-1","article-title":"Trends of incidence, mortality and survival of multiple myeloma in Spain. A twenty-three-year population-based study","volume":"23","year":"2021","journal-title":"Clin. Transl. Oncol."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1111\/bjh.17888","article-title":"Real-world data on survival improvement in patients with multiple myeloma treated at a single institution over a 45-year period","volume":"196","author":"Pereira","year":"2022","journal-title":"Br. J. Haematol."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1186\/s13045-023-01474-w","article-title":"Large-scale real-life analysis of survival and usage of therapies in multiple myeloma","volume":"16","author":"Alonso","year":"2023","journal-title":"J. Hematol. Oncol."},{"key":"ref_33","doi-asserted-by":"crossref","unstructured":"Puertas, B., Gonz\u00e1lez-Calle, V., Sobejano-Fuertes, E., Escalante, F., Queiz\u00e1n, J.A., B\u00e1rez, A., Labrador, J., Alonso-Alonso, J.M., Garc\u00eda de Coca, A., and Cantalapiedra, A. (2023). Novel Agents as Main Drivers for Continued Improvement in Survival in Multiple Myeloma. Cancers, 15.","DOI":"10.3390\/cancers15051558"}],"container-title":["Cancers"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2072-6694\/17\/5\/793\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T16:42:30Z","timestamp":1760028150000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2072-6694\/17\/5\/793"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2,25]]},"references-count":33,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2025,3]]}},"alternative-id":["cancers17050793"],"URL":"https:\/\/doi.org\/10.3390\/cancers17050793","relation":{},"ISSN":["2072-6694"],"issn-type":[{"value":"2072-6694","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,2,25]]}}}